Selected research
Industry Research
Cancer Immunotherapies Industry Research Report 2026
Market perspective
The global Cancer Immunotherapies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cancer Immunotherapies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cancer Immunotherapies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cancer Immunotherapies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cancer Immunotherapies include ARMO BioSciences (Eli Lilly), Bristol-Myers Squibb, Gilead Sciences, AstraZeneca, AbbVie, Amgen, Bayer, Pfizer and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cancer Immunotherapies market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Immunotherapies Market by Company
ARMO BioSciences (Eli Lilly)
Bristol-Myers Squibb
Gilead Sciences
AstraZeneca
AbbVie
Amgen
Bayer
Pfizer
Roche
Merck
Novartis
Johnson & Johnson
Cancer Immunotherapies Segment by Type
Immunomodulators
Checkpoint Inhibitors
Adoptive Cell transfer
Monoclonal Antibodies (MABs)
Cancer Vaccines
Cancer Immunotherapies Segment by Application
Breast Cancer
Lymphoma
Colorectal Cancer
Melanoma
Non-Small Cell Lung Cancer
Leukemia
Cancer Immunotherapies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cancer Immunotherapies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cancer Immunotherapies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cancer Immunotherapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immunomodulators
- Checkpoint Inhibitors
- Adoptive Cell transfer
- Monoclonal Antibodies (MABs)
- Cancer Vaccines
Applications
- Breast Cancer
- Lymphoma
- Colorectal Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Leukemia
Companies covered
- ARMO BioSciences (Eli Lilly)
- Bristol-Myers Squibb
- Gilead Sciences
- AstraZeneca
- AbbVie
- Amgen
- Bayer
- Pfizer
- Roche
- Merck
- Novartis
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cancer Immunotherapies Market Size (2021-2032)
- 2.2.2 Global Cancer Immunotherapies Sales (2021-2032)
- 2.2.3 Global Cancer Immunotherapies Market Average Price (2021-2032)
- 2.3 Cancer Immunotherapies by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Immunomodulators
- 2.3.3 Checkpoint Inhibitors
- 2.3.4 Adoptive Cell transfer
- 2.3.5 Monoclonal Antibodies (MABs)
- 2.3.6 Cancer Vaccines
- 2.4 Cancer Immunotherapies by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Lymphoma
- 2.4.4 Colorectal Cancer
- 2.4.5 Melanoma
- 2.4.6 Non-Small Cell Lung Cancer
- 2.4.7 Leukemia
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cancer Immunotherapies Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cancer Immunotherapies Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Cancer Immunotherapies Revenue of Manufacturers (2021-2026)
- 3.4 Global Cancer Immunotherapies Average Price by Manufacturers (2021-2026)
- 3.5 Global Cancer Immunotherapies Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cancer Immunotherapies, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cancer Immunotherapies, Product Type & Application
- 3.8 Global Manufacturers of Cancer Immunotherapies, Established Date
- 3.9 Global Cancer Immunotherapies Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ARMO BioSciences (Eli Lilly)
- 4.1.1 ARMO BioSciences (Eli Lilly) Company Information
- 4.1.2 ARMO BioSciences (Eli Lilly) Business Overview
- 4.1.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio
- 4.1.5 ARMO BioSciences (Eli Lilly) Recent Developments
- 4.2 Bristol-Myers Squibb
- 4.2.1 Bristol-Myers Squibb Company Information
- 4.2.2 Bristol-Myers Squibb Business Overview
- 4.2.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio
- 4.2.5 Bristol-Myers Squibb Recent Developments
- 4.3 Gilead Sciences
- 4.3.1 Gilead Sciences Company Information
- 4.3.2 Gilead Sciences Business Overview
- 4.3.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gilead Sciences Cancer Immunotherapies Product Portfolio
- 4.3.5 Gilead Sciences Recent Developments
- 4.4 AstraZeneca
- 4.4.1 AstraZeneca Company Information
- 4.4.2 AstraZeneca Business Overview
- 4.4.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Cancer Immunotherapies Product Portfolio
- 4.4.5 AstraZeneca Recent Developments
- 4.5 AbbVie
- 4.5.1 AbbVie Company Information
- 4.5.2 AbbVie Business Overview
- 4.5.3 AbbVie Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie Cancer Immunotherapies Product Portfolio
- 4.5.5 AbbVie Recent Developments
- 4.6 Amgen
- 4.6.1 Amgen Company Information
- 4.6.2 Amgen Business Overview
- 4.6.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Amgen Cancer Immunotherapies Product Portfolio
- 4.6.5 Amgen Recent Developments
- 4.7 Bayer
- 4.7.1 Bayer Company Information
- 4.7.2 Bayer Business Overview
- 4.7.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bayer Cancer Immunotherapies Product Portfolio
- 4.7.5 Bayer Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Cancer Immunotherapies Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Roche
- 4.9.1 Roche Company Information
- 4.9.2 Roche Business Overview
- 4.9.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Roche Cancer Immunotherapies Product Portfolio
- 4.9.5 Roche Recent Developments
- 4.10 Merck
- 4.10.1 Merck Company Information
- 4.10.2 Merck Business Overview
- 4.10.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Merck Cancer Immunotherapies Product Portfolio
- 4.10.5 Merck Recent Developments
- 4.11 Novartis
- 4.11.1 Novartis Company Information
- 4.11.2 Novartis Business Overview
- 4.11.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Novartis Cancer Immunotherapies Product Portfolio
- 4.11.5 Novartis Recent Developments
- 4.12 Johnson & Johnson
- 4.12.1 Johnson & Johnson Company Information
- 4.12.2 Johnson & Johnson Business Overview
- 4.12.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Johnson & Johnson Cancer Immunotherapies Product Portfolio
- 4.12.5 Johnson & Johnson Recent Developments
5 Global Cancer Immunotherapies Market Scenario by Region
- 5.1 Global Cancer Immunotherapies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cancer Immunotherapies Sales by Region: 2021-2032
- 5.2.1 Global Cancer Immunotherapies Sales by Region: 2021-2026
- 5.2.2 Global Cancer Immunotherapies Sales by Region: 2027-2032
- 5.3 Global Cancer Immunotherapies Revenue by Region: 2021-2032
- 5.3.1 Global Cancer Immunotherapies Revenue by Region: 2021-2026
- 5.3.2 Global Cancer Immunotherapies Revenue by Region: 2027-2032
- 5.4 North America Cancer Immunotherapies Market Facts & Figures by Country
- 5.4.1 North America Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cancer Immunotherapies Sales by Country (2021-2032)
- 5.4.3 North America Cancer Immunotherapies Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cancer Immunotherapies Market Facts & Figures by Country
- 5.5.1 Europe Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cancer Immunotherapies Sales by Country (2021-2032)
- 5.5.3 Europe Cancer Immunotherapies Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cancer Immunotherapies Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cancer Immunotherapies Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cancer Immunotherapies Market Facts & Figures by Country
- 5.7.1 South America Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cancer Immunotherapies Sales by Country (2021-2032)
- 5.7.3 South America Cancer Immunotherapies Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cancer Immunotherapies Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cancer Immunotherapies Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cancer Immunotherapies Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cancer Immunotherapies Sales by Type (2021-2032)
- 6.1.1 Global Cancer Immunotherapies Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Cancer Immunotherapies Sales Market Share by Type (2021-2032)
- 6.2 Global Cancer Immunotherapies Revenue by Type (2021-2032)
- 6.2.1 Global Cancer Immunotherapies Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cancer Immunotherapies Revenue Market Share by Type (2021-2032)
- 6.3 Global Cancer Immunotherapies Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cancer Immunotherapies Sales by Application (2021-2032)
- 7.1.1 Global Cancer Immunotherapies Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Cancer Immunotherapies Sales Market Share by Application (2021-2032)
- 7.2 Global Cancer Immunotherapies Revenue by Application (2021-2032)
- 7.2.1 Global Cancer Immunotherapies Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cancer Immunotherapies Revenue Market Share by Application (2021-2032)
- 7.3 Global Cancer Immunotherapies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cancer Immunotherapies Value Chain Analysis
- 8.1.1 Cancer Immunotherapies Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cancer Immunotherapies Production Mode & Process
- 8.2 Cancer Immunotherapies Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cancer Immunotherapies Distributors
- 8.2.3 Cancer Immunotherapies Customers
9 Global Cancer Immunotherapies Analyzing Market Dynamics
- 9.1 Cancer Immunotherapies Industry Trends
- 9.2 Cancer Immunotherapies Industry Drivers
- 9.3 Cancer Immunotherapies Industry Opportunities and Challenges
- 9.4 Cancer Immunotherapies Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst